Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $66.05M |
| Gross Profit (TTM) | $-288.47M |
| EBITDA | $-470.27M |
| Operating Margin | -530.00% |
| Return on Equity | -32.80% |
| Return on Assets | -21.70% |
| Revenue/Share (TTM) | $1.13 |
| Book Value | $18.69 |
| Price-to-Book | 0.69 |
| Price-to-Sales (TTM) | 25.34 |
| EV/Revenue | 23.87 |
| EV/EBITDA | -2.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 137.70% |
| Shares Outstanding | $59.47M |
| Float | $53.13M |
| % Insiders | 1.09% |
| % Institutions | 108.57% |
Volatility is currently contracting